NCT04026750 - Insulin Tolerance Test Study in Patients With Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 15, 2019

Primary Completion Date

February 16, 2020

Study Completion Date

February 16, 2020

Conditions

Type 1 DiabetesHypoglycemia

Interventions

DRUG

Pitolisant

Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.

Trial Locations (1)

High Point Clinical Trials Center, High Point